FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 492 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to... January 20, 2021 The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic... April 16, 2021 Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer May 5, 2021 Load more HOT NEWS Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors A Daily Survival Kit for Serious Illness How TRACERx is helping us predict lung cancer’s next move
